Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
Abstract Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations.
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-11-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.5057 |
| _version_ | 1818997625570983936 |
|---|---|
| author | David Bobrowski Reha Kumar Peter E. Wu Lauren Lapointe‐Shaw |
| author_facet | David Bobrowski Reha Kumar Peter E. Wu Lauren Lapointe‐Shaw |
| author_sort | David Bobrowski |
| collection | DOAJ |
| description | Abstract Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations. |
| first_indexed | 2024-12-20T21:48:37Z |
| format | Article |
| id | doaj.art-34c939d53002417eb7eb7864524bb8df |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-12-20T21:48:37Z |
| publishDate | 2021-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-34c939d53002417eb7eb7864524bb8df2022-12-21T19:25:37ZengWileyClinical Case Reports2050-09042021-11-01911n/an/a10.1002/ccr3.5057Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapyDavid Bobrowski0Reha Kumar1Peter E. Wu2Lauren Lapointe‐Shaw3Department of Medicine University of Toronto Toronto Ontario CanadaDepartment of Medicine University of Toronto Toronto Ontario CanadaDepartment of Medicine University of Toronto Toronto Ontario CanadaDepartment of Medicine University of Toronto Toronto Ontario CanadaAbstract Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations.https://doi.org/10.1002/ccr3.5057diabeteseuglycemic diabetic ketoacidosissodium‐glucose cotransporter 2 inhibitors |
| spellingShingle | David Bobrowski Reha Kumar Peter E. Wu Lauren Lapointe‐Shaw Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy Clinical Case Reports diabetes euglycemic diabetic ketoacidosis sodium‐glucose cotransporter 2 inhibitors |
| title | Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy |
| title_full | Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy |
| title_fullStr | Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy |
| title_full_unstemmed | Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy |
| title_short | Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy |
| title_sort | prolonged ketosis and glycosuria secondary to sglt2 inhibitor therapy |
| topic | diabetes euglycemic diabetic ketoacidosis sodium‐glucose cotransporter 2 inhibitors |
| url | https://doi.org/10.1002/ccr3.5057 |
| work_keys_str_mv | AT davidbobrowski prolongedketosisandglycosuriasecondarytosglt2inhibitortherapy AT rehakumar prolongedketosisandglycosuriasecondarytosglt2inhibitortherapy AT peterewu prolongedketosisandglycosuriasecondarytosglt2inhibitortherapy AT laurenlapointeshaw prolongedketosisandglycosuriasecondarytosglt2inhibitortherapy |